{
    "organizations": [],
    "uuid": "805f3bd7104cdf39decde40bb7d65edb135f3e6f",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-pfizer-announces-favorable-outcome/brief-pfizer-announces-favorable-outcome-of-fda-advisory-committee-meeting-idUSFWN1QQ0ZY",
    "ord_in_thread": 0,
    "title": "BRIEF-Pfizer Announces Favorable Outcome Of FDA Advisory Committee Meeting",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 8 (Reuters) - Pfizer Inc:\n* PFIZER ANNOUNCES FAVORABLE OUTCOME OF FDA ADVISORY COMMITTEE MEETING ON XELJANZ® (TOFACITINIB) FOR MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS\n* PFIZER INC - ‍FDA’S DECISION ON WHETHER OR NOT TO APPROVE TOFACITINIB FOR UC IS EXPECTED BY PRESCRIPTION DRUG USER FEE ACT (PDUFA) DATE IN JUNE 2018​ Source text for Eikon: Further company coverage:\nOur Standards: The Thomson Reuters Trust Principles.",
    "published": "2018-03-09T06:02:00.000+02:00",
    "crawled": "2018-03-09T14:31:33.022+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "pfizer",
        "inc",
        "pfizer",
        "announces",
        "favorable",
        "outcome",
        "fda",
        "advisory",
        "committee",
        "meeting",
        "tofacitinib",
        "moderately",
        "severely",
        "active",
        "ulcerative",
        "colitis",
        "pfizer",
        "inc",
        "decision",
        "whether",
        "approve",
        "tofacitinib",
        "uc",
        "expected",
        "prescription",
        "drug",
        "user",
        "fee",
        "act",
        "pdufa",
        "date",
        "june",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "standard",
        "thomson",
        "reuters",
        "trust",
        "principle"
    ]
}